Teladoc Health, Inc. (TDOC) · Oct 28, 2026 · Earnings

Teladoc earnings beat as BetterHelp cash-pay revenue plunges

Beat — Revenue $605.1M vs ~$588.5M consensus; adjusted EBITDA $79.4M vs $62M-$74M guide

Teladoc’s Q3 earnings beat revenue and EBITDA expectations, while BetterHelp’s insurance transition deepened the decline in cash-pay demand.

Teladoc is in an execution phase: strengthening its employer-and-health-plan Integrated Care business, rolling out Teladoc One, and shifting BetterHelp from direct cash pay toward insurance-covered therapy. That transition is intended to broaden access, but it is also pressuring the legacy consumer model.

The quarter beat the market’s operating expectations. Revenue reached $605.1 million versus a published consensus of roughly $588.5 million, while diluted loss per share was $0.15 versus an expected loss of about $0.22. Adjusted EBITDA was $79.4 million, above the company’s prior $62 million-$74 million range. Revenue was near the top of management’s range, and profitability was clearly above it.

MetricQ3 2026Comparison / expectation
Revenue$605.1M~$588.5M consensus; $626.4M year ago
Net loss per share$(0.15)$(0.28) year ago; ~$$(0.22) consensus
Adjusted EBITDA$79.4M$62M-$74M prior guide; $69.9M year ago
Integrated Care revenue$398.5M+2% year over year
Integrated Care adjusted EBITDA$74.9M+13% year over year; 18.8% margin
BetterHelp revenue$206.6M-13% year over year
BetterHelp adjusted EBITDA$4.5M+17% year over year; 2.2% margin
Nine-month free cash flow$85.4M$113.5M year ago
Full-year revenue outlook$2.395B-$2.441BPrior range: $2.362B-$2.447B
Full-year adjusted EBITDA outlook$277M-$303MPrior range: $271M-$303M

Integrated Care is carrying the business. Segment revenue grew 2%, adjusted EBITDA rose 13%, and the margin expanded to 18.8%, suggesting the core employer, health-plan, and enterprise-care operation is executing better even while consolidated revenue remains down.

BetterHelp’s transition is working directionally but not yet financially. Insurance-covered revenue jumped to $32.1 million from $3.7 million, but Consumer and Other revenue fell 25% to $174.5 million, leaving total BetterHelp revenue down 13%. The filing confirms that insurance adoption is replacing cash-pay revenue faster than the new channel can offset it.

Management modestly improved the full-year framework, but mainly on profitability rather than growth. The revenue range moved higher at the low end and lower at the high end, while the adjusted EBITDA range rose from $271 million-$303 million to $277 million-$303 million. Free-cash-flow guidance also narrowed to $135 million-$165 million from $130 million-$170 million. That is a better execution signal, not a return to broad-based revenue growth.

Cash generation remains a blemish beneath the EBITDA beat. Nine-month operating cash flow fell to $180.6 million from $206.6 million, and free cash flow dropped to $85.4 million from $113.5 million, even though third-quarter cash flow improved. The company ended with $849.9 million of cash, but nearly $1.0 billion of convertible notes is classified as current, making cash conversion and balance-sheet management relevant to the next phase.

Bottom line: This is a genuine earnings beat led by Integrated Care and better cost control, with guidance modestly tightened upward. The central turnaround issue is unresolved: BetterHelp is gaining insurance revenue, but the cash-pay decline still overwhelms that progress at the consolidated level.

What to watch next

Q4 report and January Teladoc One launch

Original filing on SEC EDGAR

More Teladoc Health, Inc. news

Teladoc earnings beat as BetterHelp cash-pay revenue plunges | TDOC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.